You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 17, 2025

Drugs in ATC Class H02C


✉ Email this page to a colleague

« Back to Dashboard


Subclasses in ATC: H02C - ANTIADRENAL PREPARATIONS

H02C Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class H02C (Antiadrenal Preparations) reveal a sector driven by innovation in endocrine disorder treatments, particularly for conditions like Cushing’s syndrome. Below is a structured analysis:


Market Dynamics

Growth Drivers

  • Rising Prevalence of Cushing’s Syndrome: The global market for Cushing’s syndrome treatments, valued at US$385.2 million in 2023, is projected to grow at a CAGR of 7.25% to reach US$831.7 million by 2034[16]. Growth is fueled by increased corticosteroid use for chronic diseases (e.g., asthma, rheumatoid arthritis) and advancements in diagnostic technologies[16].
  • Emerging Therapies: Novel drugs like osilodrostat (approved in the EU and U.S. for Cushing’s disease) and levoketoconazole (an enantiomer of ketoconazole) are expanding treatment options[14][17]. These agents inhibit cortisol synthesis or adrenal steroidogenesis, offering targeted efficacy[2][7].
  • Minimally Invasive Treatments: Adoption of laparoscopic adrenalectomy and combination therapies (surgery + medical management) improves patient outcomes and reduces recovery times[16].

Challenges

  • High Treatment Costs: Newer therapies like osilodrostat are expensive, limiting accessibility in lower-income regions[16].
  • Regulatory Hurdles: Stringent approval processes delay drug launches, as seen with trilostane, which lacks FDA approval despite clinical use in Europe[4].

Key Players

  • Osilodrostat (Novartis) dominates recent approvals, with 6 active patents and clinical trials targeting hypercortisolism management[14][17].
  • Ketoconazole remains a cost-effective option but faces competition due to side effects (e.g., hepatotoxicity)[7].
  • Relacorilant (Corcept Therapeutics) is in late-stage trials as a glucocorticoid receptor antagonist, aiming to overcome limitations of older therapies like mifepristone[18].

Patent Landscape

Active Patents

  1. Osilodrostat: Protected under multiple patents (e.g., WO2016073774) covering its use in cortisol synthesis inhibition[14].
  2. AKT Kinase Inhibitors: Compounds like hydroxylated pyrimidyl cyclopentanes (TW200817373A) show potential for anticancer applications, overlapping with adrenal-related pathways[2].
  3. Immunoregulatory Agents: Abandoned Canadian patent CA2964297 highlights ongoing R&D in immunomodulation for endocrine disorders[13].

Generics and Expiries

  • Ketoconazole: Off-patent, with generic versions widely available[7].
  • Trilostane: Limited patent protection outside Europe, creating opportunities for biosimilars[4].

Competitive Strategies

  • Product Differentiation: Companies focus on oral inhibitors (e.g., osilodrostat) to replace invasive therapies[14].
  • Combination Therapies: Trials pairing steroidogenesis inhibitors (e.g., levoketoconazole) with immunotherapy or ACTH receptor blockers (e.g., CRN04894) aim to enhance efficacy[18].
  • Geographic Expansion: Novartis and Corcept Therapeutics prioritize North America and Europe, while Asian markets see growth in generics[9][16].

Regional Insights

Region Market Share Key Trends
North America 45% Dominated by high healthcare spending and strong IP protections[16].
Europe 30% Growth driven by osilodrostat approvals and EU-wide guidelines[14].
Asia-Pacific 20% Rising demand for cost-effective generics and improved diagnostics[9][16].

Future Outlook

  • Innovation in Drug Delivery: Long-acting injectables and oral formulations aim to improve patient compliance[16].
  • Targeted Therapies: Pipeline drugs like relacorilant and CRN04894 (ACTH antagonist) could reduce reliance on surgery[18].
  • Patent Cliffs: Expiry of osilodrostat’s patents post-2030 may open doors for generics, intensifying price competition[14].

"The introduction of improved delivery methods for medications, including long-acting injections, is expected to drive market growth by enhancing adherence."
Cushing’s Syndrome Market Report[16].


Key Takeaways

  1. The H02C market is growing rapidly due to innovative therapies and rising endocrine disorder prevalence.
  2. Osilodrostat’s patents and clinical success position it as a near-term market leader.
  3. Cost pressures and regulatory challenges necessitate strategic partnerships for R&D and distribution.

FAQs

Q: What is the primary use of H02C drugs?
A: They treat hypercortisolism in conditions like Cushing’s syndrome by inhibiting adrenal steroid production[4][14].

Q: Which regions lead in H02C drug adoption?
A: North America and Europe, driven by advanced healthcare infrastructure and regulatory support[16].

Q: How does osilodrostat differ from ketoconazole?
A: Osilodrostat selectively inhibits cortisol synthesis, whereas ketoconazole has broader antifungal effects and off-target toxicity[7][14].

Q: Are there generic alternatives for H02C drugs?
A: Yes, ketoconazole and trilostane have generics, but newer agents like osilodrostat remain under patent[4][7].

Q: What future trends could disrupt this market?
A: Immunotherapies targeting ACTH receptors and oral nonpeptide antagonists (e.g., CRN04894) may redefine treatment paradigms[18].

References

  1. https://www.cognitivemarketresearch.com/atc-displays-market-report
  2. https://patents.google.com/patent/TW200817373A/en
  3. https://en.wikipedia.org/wiki/ATC_code_H02
  4. https://go.drugbank.com/drugs/DB01108
  5. https://www.economicsonline.co.uk/definitions/atc-curve.html/
  6. https://pubchem.ncbi.nlm.nih.gov/compound/Osilodrostat
  7. https://go.drugbank.com/drugs/DB01026
  8. https://www.youtube.com/watch?v=akS3hWixQyI
  9. https://www.chemanalyst.com/NewsAndDeals/NewsDetails/global-2-eh-prices-stabilize-amid-supply-shifts-and-looming-cost-pressures-34511
  10. https://archive.org/stream/officialgazette912unit/officialgazette912unit_djvu.txt
  11. https://www.atccode.com/H02C
  12. https://www.tipranks.com/stocks/au:atc
  13. https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2964297/summary.html?wbdisable=true
  14. https://go.drugbank.com/drugs/DB11837
  15. https://pubchem.ncbi.nlm.nih.gov/compound/3823
  16. https://www.imarcgroup.com/cushings-syndrome-market
  17. https://go.drugbank.com/categories/DBCAT002504
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC11548364/
Last updated: 2025-03-23

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.